Study results spark 13% drop in Perspective Therapeutics shares – Radiation levels in focus

Shares of Perspective Therapeutics (NYSE AMERICAN: CATX) fell sharply, dropping over 13% to $11.49, after the latest data from their Phase 1/2a study on a ... Read More